Featured Research

from universities, journals, and other organizations

Gene Therapy Works In Mice To Prevent Blindness That Strikes Boys

Date:
August 16, 2005
Source:
University of Florida
Summary:
Scientists from the UF Genetics Institute describe how they successfully used gene therapy in mice to treat retinoschisis, a rare genetic disorder that is passed from mothers, who retain their sight, to their sons.

GAINESVILLE, Fla. - University of Florida scientists used a healthyhuman gene to prevent blindness in mice with a form of an incurable eyedisease that strikes boys.

Writing in the August issue of Molecular Therapy, scientists fromthe UF Genetics Institute describe how they successfully used genetherapy in mice to treat retinoschisis, a rare genetic disorder that ispassed from mothers, who retain their sight, to their sons.

"Currently there is no treatment," said William Hauswirth,Ph.D., the Rybaczki-Bullard professor of ophthalmic molecular genetics."These children lose their sight gradually, often with devastatingresults. What happens is the retina actually begins to split in themiddle, causing loss of central vision - that's the vision that youneed to be able to read or walk around."

Scientists say the gene transfer method eventually could beapplied to many eye diseases caused by single gene defects, including ahost of retinal disorders.

Retinoschisis is usually first detected in boys between 5 and10 years of age when their vision problems cause reading difficulties.In a healthy eye, retinal cells secrete a protein called retinoschisin,or RS1, which acts like glue to connect the layers of the retina.Without it, the layers separate and tiny cysts form, devastating thevision and often leading to blindness in about 1 of every 5,000 boys.

UF researchers injected a healthy version of the human RS1gene to the sub-retinal space of the right eyes of 15-day-old malemice, which, like boys with the disease, don't have the healthy gene tomaintain the retina. In terms of disease development, the condition inthe mice was roughly equivalent to retinoschisis in a 10-year-old boy.

Six months later, researchers looked at the interior of theeyes with a laser ophthalmoscope and found cyst formation was clearlyevident in the untreated eyes, but the treated eyes appeared healthy.The eye's photoreceptor cells - the rods and cones that help the brainprocess light and color - were spared from the disease and theconnections between the layers of the retinas were intact.

In addition, the protein appears capable of moving within theretina to its target sites and the beneficial changes appear to be longlasting, researchers said. Especially encouraging were signs thetreatment may be able to repair retinal damage.

The treatment has promising implications for other genetic eyediseases that involve the eye's ability to process light, includingretinitis pigmentosa, which affects about 200,000 people in the UnitedStates and is one of the most common inherited causes of blindness inpeople between the ages of 20 and 60.

"We've been very successful in curing a disease in mice thathas a direct copy in humans," said Hauswirth, who, in conjunction withUF, has interest in a biotechnology company that may seek to marketsome of the research technology. "It may take two to five years beforewe try this in human patients because of the need for safety studies,but we feel based on success so far, we will be able to provide formalevidence for safety that will allow us to get treatment into theclinic."

UF researchers worked with Bernhard Weber, Ph.D., at theInstitute of Human Genetics in Regensburg, Germany, and Robert Molday,Ph.D., director of the Center for Macular Research at the University ofBritish Columbia in Vancouver.

The Foundation Fighting Blindness, the National Institutes ofHealth and the Macula Vision Research Foundation supported theresearch.

"We now have proof of principle that gene therapy can basicallyprevent retinoschisis," said Stephen Rose, Ph.D., chief researchofficer for the Maryland-based Foundation Fighting Blindness."Furthermore, this therapy apparently demonstrates that even if diseasehas begun, there is a healing that takes place. That raises hope forsuffering patients that we may be able to offer something that canimprove the quality of their lives."


Story Source:

The above story is based on materials provided by University of Florida. Note: Materials may be edited for content and length.


Cite This Page:

University of Florida. "Gene Therapy Works In Mice To Prevent Blindness That Strikes Boys." ScienceDaily. ScienceDaily, 16 August 2005. <www.sciencedaily.com/releases/2005/08/050814170130.htm>.
University of Florida. (2005, August 16). Gene Therapy Works In Mice To Prevent Blindness That Strikes Boys. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/08/050814170130.htm
University of Florida. "Gene Therapy Works In Mice To Prevent Blindness That Strikes Boys." ScienceDaily. www.sciencedaily.com/releases/2005/08/050814170130.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins